The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
 
Chemical Compound Review

Difluoro     difluorophosphorylmethane

Synonyms: HSDB 7668, AR-1J6724, LS-106867, BRN 1739375, AC1L2C9H, ...
 
 
Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.
 

Disease relevance of difluorophosphorylmethane

 

High impact information on difluorophosphorylmethane

  • When incubated with Krebs' bicarbonate solution (pH 7.4) at 37 degrees C, the biological half-life of the difluoro analog was about 24 hr compared to the 10- to 15-min half-life of PGI2 under similar conditions [3].
  • The difluoro analog was 3- to 4-fold more active than PGI2 in causing relaxation of both types of strips and appeared at least equipotent to PGI2 in its blood pressure lowering effect in dogs [3].
  • The decomposition of diradicals resulting from a cleavage of C-C and Si-C bonds in 2 is exothermic by 24.3-3.3 kcal/mol (apart from the difluoro derivative which is endothermic by 5.1 kcal/mol) and 27.0-13.3 kcal/mol, respectively [4].
  • Mono- or difluoro substitution at meta position(s), as in 22c and 22h, was advantageous for both in vitro COX-2 potency and selectivity (e.g., COX-2 IC(50) for 22c = 1 microM and COX-1 IC(50) for 22c = 20 microM in HWB assay) [5].
  • Previous studies in our laboratory using substrate-based difluoro ketone and difluoro alcohol transition-state analogue inhibitors suggest that gamma-secretase is an aspartyl protease with loose sequence specificity [6].
 

Biological context of difluorophosphorylmethane

 

Anatomical context of difluorophosphorylmethane

  • These constants indicate that the maxilloturbinates in the anterior of the nose receive more than four times the dose of difluoro than do the ethmoturbinates, whereas the trachea and lung receive much lower doses than do the nasal tissues [8].
  • Of interest, the slopes of the concentration-dependence lines of the difluoro- and dibromo-acetates were markedly dissimilar from the other di- and tri-haloacetates, suggesting either a marked difference in the way they activate the PPARalpha receptor or a substantial difference in the way they are metabolized or transported by the hepatocytes [10].
  • 7. These results indicate the difluoro and 4-fluoro analogues of ciprofibrate and clofibric acid are hypolipidaemic agents and peroxisome proliferators but with reduced potencies relative to the parent molecules [11].
  • Flunarizine, a difluoro derivative of cinnarizine, has been used to study its antivasoconstrictor effects on isolated perfused rat mesentery [12].
 

Associations of difluorophosphorylmethane with other chemical compounds

 

Gene context of difluorophosphorylmethane

  • The difluoro analog dFdG was an efficient substrate for recombinant dGK with an apparent Km of 16 microM with ATP as phosphate donor [16].
  • We report herein that, like camptothecins, homocamptothecin and its difluoro derivative BN80915 are substrates for ABCG2 [17].
  • Compared to their nonfluorinated parent compounds all the difluoro analogues were poorer inhibitors of TS [13].
  • The combination of CyA with RAPA, a macrolide which inhibits lymphokine signal transduction, and with BQR, a difluoro quinoline carboxylic acid analog that inhibits pyrimidine biosynthesis, permits at least a 20-fold reduction of the CyA dose in rat allograft models as well as prevents the activation of some CyA-resistant rejection pathways [18].
 

Analytical, diagnostic and therapeutic context of difluorophosphorylmethane

References

  1. Design, synthesis, and antiviral evaluation of 2-chloro-5,6-dihalo-1-beta-D-ribofuranosylbenzimidazoles as potential agents for human cytomegalovirus infections. Zou, R., Drach, J.C., Townsend, L.B. J. Med. Chem. (1997) [Pubmed]
  2. In vitro activity of temafloxacin, a new difluoro quinolone antimicrobial agent. Chin, N.X., Figueredo, V.M., Novelli, A., Neu, H.C. Eur. J. Clin. Microbiol. Infect. Dis. (1988) [Pubmed]
  3. Vascular relaxing activity and stability studies of 10,10-difluoro-13,14-dehydroprostacyclin. Hatano, Y., Kohli, J.D., Goldberg, L.I., Fried, J., Mehrotra, M.M. Proc. Natl. Acad. Sci. U.S.A. (1980) [Pubmed]
  4. Effect of geminal substitution at silicon on 1-sila- and 1,3-disilacyclobutanes' strain energies, their 2+2 cycloreversion enthalpies, and Si=C pi-bond energies in silenes. Gusel'nikov, L.E., Avakyan, V.G., Guselnikov, S.L. J. Am. Chem. Soc. (2002) [Pubmed]
  5. Synthesis and structure-activity relationship of novel, highly potent metharyl and methcycloalkyl cyclooxygenase-2 (COX-2) selective inhibitors. Khanapure, S.P., Garvey, D.S., Young, D.V., Ezawa, M., Earl, R.A., Gaston, R.D., Fang, X., Murty, M., Martino, A., Shumway, M., Trocha, M., Marek, P., Tam, S.W., Janero, D.R., Letts, L.G. J. Med. Chem. (2003) [Pubmed]
  6. Difluoro ketone peptidomimetics suggest a large S1 pocket for Alzheimer's gamma-secretase: implications for inhibitor design. Moore, C.L., Leatherwood, D.D., Diehl, T.S., Selkoe, D.J., Wolfe, M.S. J. Med. Chem. (2000) [Pubmed]
  7. The inhibition of rat and guinea pig cholinesterases by anionic hydrolysis products of methylphosphonic difluoride (difluoro). Dahl, A.R., Hobbs, C.H., Marshall, T.C. Toxicol. Appl. Pharmacol. (1986) [Pubmed]
  8. Deposition and clearance of a water-reactive vapor, methylphosphonic difluoride (difluoro), inhaled by rats. Dahl, A.R., Bechtold, W.E. Toxicol. Appl. Pharmacol. (1985) [Pubmed]
  9. Sequence-specific DNA alkylation of novel tallimustine derivatives. Marchini, S., Cozzi, P., Beria, I., Geroni, C., Capolongo, L., D'Incalci, M., Broggini, M. Anticancer Drug Des. (1998) [Pubmed]
  10. Induction of peroxisome proliferation in cultured hepatocytes by a series of halogenated acetates. Walgren, J.L., Jollow, D.J., McMillan, J.M. Toxicology (2004) [Pubmed]
  11. Comparative hypolipidaemic and peroxisomal effects of ciprofibrate, clofibric acid, and their respective difluorocyclopropyl and 4-fluoro-substituted analogues in rat. Graham, M.J., Winham, M.A., Old, S.L., Gray, T.J. Xenobiotica (1996) [Pubmed]
  12. Pharmacodynamic studies with flunarizine, a calcium influx blocker. Gulati, N., Huggel, H., Gulati, O.P. Archives internationales de pharmacodynamie et de thérapie. (1983) [Pubmed]
  13. Quinazoline antifolate thymidylate synthase inhibitors: difluoro-substituted benzene ring analogues. Thornton, T.J., Jackman, A.L., Marsham, P.R., O'Connor, B.M., Bishop, J.A., Calvert, A.H. J. Med. Chem. (1992) [Pubmed]
  14. Comparative in vitro activity of the new difluoro-quinolone temafloxacin (A-62254) against bacterial isolates from cancer patients. Rolston, K.V., Ho, D.H., LeBlanc, B., Gooch, G., Bodey, G.P. Eur. J. Clin. Microbiol. Infect. Dis. (1988) [Pubmed]
  15. Effect of flunarizine on calcium-induced responses of peripheral vascular smooth muscle. Van Nueten, J.M., Van Beek, J., Janssen, P.A. Archives internationales de pharmacodynamie et de thérapie. (1978) [Pubmed]
  16. Phosphorylation of anticancer nucleoside analogs by human mitochondrial deoxyguanosine kinase. Zhu, C., Johansson, M., Permert, J., Karlsson, A. Biochem. Pharmacol. (1998) [Pubmed]
  17. ABCG2 mediates differential resistance to SN-38 (7-ethyl-10-hydroxycamptothecin) and homocamptothecins. Bates, S.E., Medina-Pérez, W.Y., Kohlhagen, G., Antony, S., Nadjem, T., Robey, R.W., Pommier, Y. J. Pharmacol. Exp. Ther. (2004) [Pubmed]
  18. Optimization of cyclosporine therapy. Kahan, B.D. Transplant. Proc. (1993) [Pubmed]
  19. Difluoro complexes of platinum(II) and -(IV) with monodentate phosphine ligands: an exceptional stability of d6 octahedral organometallic fluorides. Yahav, A., Goldberg, I., Vigalok, A. Inorganic chemistry. (2005) [Pubmed]
  20. Metabolism and biological activity of all-trans 4,4-difluororetinyl acetate. Barua, A.B., Olson, J.A. Biochim. Biophys. Acta (1984) [Pubmed]
 
WikiGenes - Universities